Document Detail


Mesalamine in the treatment and maintenance of remission of ulcerative colitis.
MedLine Citation:
PMID:  22390554     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Ulcerative colitis (UC) is a chronic disease of the GI tract that is characterized by mucosal inflammation in the colon. Mesalamine (mesalazine) is a 5-aminosalicylic acid compound that is the first-line treatment for patients with mild-to-moderate UC. There are multiple formulations of mesalamine available, primarily differentiated by their means of delivering active mesalamine to the colon. Mesalamine has been demonstrated in randomized controlled trials to induce both clinical response and remission, and maintain clinical remission, in these patients. It has few serious adverse effects and is generally well tolerated by patients. The main areas of uncertainty with use of mesalamine in patients with UC center on the optimal dose for induction of response, how to maintain patient adherence and the role of mesalamine in cancer chemoprophylaxis. Generic forms of mesalamine have yet to be approved by regulatory bodies in the USA.
Authors:
Maggie Ham; Alan C Moss
Related Documents :
17170874 - Limits of the transoral approach in craniospinal malformations.
6483134 - Modified crossed leg raising test and sciatica.
20674124 - Effects of class iii malocclusion on young male adults' vocal tract development: a pilo...
21397424 - Presence of anti-borrelia burgdorferi antibodies and borrelia burgdorferi sensu lato dn...
3377464 - Pharmacokinetics of imipenem-cilastatin in patients with renal insufficiency undergoing...
9373264 - Adult patients with de novo acute myeloid leukemia and t(9; 11)(p22; q23) have a superi...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Review    
Journal Detail:
Title:  Expert review of clinical pharmacology     Volume:  5     ISSN:  1751-2441     ISO Abbreviation:  Expert Rev Clin Pharmacol     Publication Date:  2012 Mar 
Date Detail:
Created Date:  2012-03-06     Completed Date:  2012-05-29     Revised Date:  2014-09-08    
Medline Journal Info:
Nlm Unique ID:  101278296     Medline TA:  Expert Rev Clin Pharmacol     Country:  England    
Other Details:
Languages:  eng     Pagination:  113-23     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Aged, 80 and over
Anti-Inflammatory Agents, Non-Steroidal / adverse effects,  pharmacology,  therapeutic use*
Child
Child, Preschool
Colitis, Ulcerative / complications,  drug therapy*
Humans
Infant
Mesalamine / adverse effects,  pharmacology,  therapeutic use*
Middle Aged
Patient Compliance
Randomized Controlled Trials as Topic
Remission Induction
Severity of Illness Index
Therapeutic Equivalency
Treatment Outcome
Young Adult
Grant Support
ID/Acronym/Agency:
K23 DK084338/DK/NIDDK NIH HHS; K23 DK084338-01A2/DK/NIDDK NIH HHS; K23DK084338/DK/NIDDK NIH HHS
Chemical
Reg. No./Substance:
0/Anti-Inflammatory Agents, Non-Steroidal; 4Q81I59GXC/Mesalamine
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Treatment of Localized Gingival Recessions Using Gingival Unit Grafts: A Randomized Controlled Clini...
Next Document:  Octreotide long-acting repeatable for acromegaly.